▲ Peaking
Health
I lost the weight on a GLP-1
GLP‑1 weight‑loss drugs spark a clash between life‑changing results and fears of inevitable rebound.
Obesity
24 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Obesity
This hub groups 24 separate news trends connected to Obesity, spanning June 18, 2026 through August 31, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 167 article observations and 163 source signals, led by Health, Business coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Health
The middle-aged disease that makes you feel tired and often goes undiagnosed
A rise in liver disease among younger adults and those with diabetes is sparking concern among health professionals.
◼ Archived
Business
🔮 fades ✓
Roche pens $2.5B pact for Hanmi’s clinical-stage obesity drug targeting less-explored mechanism
Roche’s $2.5 billion pact for Hanmi’s muscle‑sparing obesity drug ignites expectations for a new weight‑loss breakthrough
◼ Archived
Health
🔮 fades ✓
Promising new weight loss and diabetes treatment helps burn fat while keeping muscle in preclinical study
A new treatment could revolutionize weight loss and diabetes management by targeting fat while preserving muscle.
◼ Archived
Health
🔮 fades ✓
Could GLP-1s help with alcohol use disorder? A Philly VA doctor is leading a national trial to find out.
A national trial is exploring whether GLP-1s, known for weight loss, can also help with alcohol use disorder.
◼ Archived
Health
🔮 fades ✓
Why Three Minutes Of Sprinting May Beat An Hour+ Spent Exercising
A 3-minute sprinting routine may offer health benefits comparable to an hour of moderate exercise.
◼ Archived
Health
🔮 fades ✓
Your waistline could reveal a hidden heart risk your BMI misses, major study finds
A major study suggests waist size may better predict heart disease risk than BMI.
◼ Archived
Health
🔮 fades ✓
GLP-1s May Be Working in an Entirely Different Way Than We Thought
New research suggests that popular weight-loss drugs may work differently than previously understood.
◼ Archived
Health
🔮 fades ✓
Lilly's weight-loss pill gets UK regulator's nod
The UK has approved a new weight-loss pill, marking a significant shift in obesity treatment options.
◼ Archived
Business
🔮 fades ✓
How Ozempic maker Novo Nordisk blew its lead in GLP-1 weight-loss drugs. Can Europe compete in the high-stakes global economy?
Novo Nordisk faces intensifying competition from Eli Lilly in the global GLP-1 weight-loss market as its early industry lead faces significant pressure.
◼ Archived
Health
🔮 holds ✗
GLP-1 use tied to obesity decline, but doctors warn of alarming misuse
GLP-1 drugs are linked to a decline in obesity, but doctors are raising alarms about misuse.
◼ Archived
Health
🔮 fades ✓
Where You Carry Your Body Fat Is Directly Linked to Brain Aging in First-of-Its-Kind Study
New research indicates a direct link between the location of body fat and the rate of brain aging and memory loss.
◼ Archived
Business
🔮 fades ✓
Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data
Eli Lilly is advancing toward a 2027 regulatory filing for retatrutide following successful Phase 3 obesity trial results.
◼ Archived
Health
🔮 holds ✗
GLP-1 use rising rapidly among US adolescents and young adults, study finds
GLP-1 weight-loss medications are seeing a rapid surge in use among U.S. adolescents and young adults.
◼ Archived
Health
🔮 fades ✓
More young women in their 20s are getting type 2 diabetes
Health officials are warning of a 'health time bomb' as Type 2 diabetes cases surge among women in their 20s and those under 40.
◼ Archived
Health
🔮 fades ✓
This GLP-1 retreat changed how I think about weight loss
GLP-1 medications are sparking broader conversations about weight loss retreats, medical benefits beyond weight, and the psychological impact of stigma.
◼ Archived
Health
🔮 fades ✓
Too many Britons are too fat to work
A new study reveals that over 600,000 people in the UK are unable to work due to obesity.
◼ Archived
Health
🔮 fades ✓
GLP-1’s Reduce Binge Eating Symptoms
Research suggests GLP-1 medications like Ozempic and Wegovy may provide a promising treatment for binge eating disorder.
◼ Archived
Business
🔮 fades ✗
11% of Americans Are Currently Taking a GLP-1 Weight Loss Drug Like Wegovy
GLP-1 weight loss drugs are being used by a record number of Americans.
◼ Archived
Health
🔮 fades ✓
About 170,000 people in England expected to die from obesity-linked heart conditions by 2035
New research warns of a grim future for England's heart health due to rising obesity rates
◼ Archived
Health
🔮 fades ✓
The negative impacts of fruit juices and other sugary treats for children
Recent studies highlight the long-term health risks of sugary beverages for children.
◼ Archived
Health
🔮 fades ✓
Research shows weight-loss drugs may also reduce cancer risk
New research indicates GLP-1 receptor agonists used for weight loss may be linked to a reduced risk of certain cancers, specifically breast cancer.
◼ Archived
Health
🔮 fades ✓
The "dad bod," explained by science
Recent scientific analysis examines the 'dad bod' and how paternal obesity and diet impact the long-term health of children.
◼ Archived
Health
🔮 fades ✓
Ozempic users may be making a major weight-loss mistake, new study suggests
New research indicates a trend of decreased physical activity among individuals using GLP-1 weight loss medications like Ozempic and Wegovy.